recently reported among a cohort of 1012 patients with a stage I-III lung adenocarcinoma that KRAS G12C mutations are associated with a significant shorter OS and relapse-free survival, compared with other KRAS mutations and wild-type KRAS (30). The gene discussed is KRAS; the disease is lung adenocarcinoma.